1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. International Agency for Research on Cancer (IARC): Lyon, 2008.
2. Vardiman JW, Bennett JM, Bain B, Brunning RD, Thiele J . Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th edn. International Agency for Research on Cancer (IARC): Lyon, p 80–81 2008.
3. Fend F, Horn T, Koch I, Vela T, Orazi A . Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. Leuk Res 2008; 32: 1931–1935.
4. Bacher U, Schnittger S, Kern W, Weiss T, Haferlach T, Haferlach C . Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category. Ann Hematol 2009; 88: 1207–1213.
5. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.